{"title":"基于COVID-19疫苗研究进展的强生公司财务分析","authors":"Khalifa Alhosnai, Kaushang Kharbanda, Hessa Saeed Almazrouei, Asma Ibrahim Alzaabi, Wafaa Aldhanhani, Souhail Mostafa, Shaima Mohamed Alhajiri, Haitham Nobanee","doi":"10.2139/ssrn.3896177","DOIUrl":null,"url":null,"abstract":"Amid the recent developments regarding the Johnson & Johnson vaccination pause and investigation, an opportunity was created to observe and analyze the financial changes to the company's profile that had taken place as a result of the incident, to understand the impacts and effects of the decisions taken by the firm and previous occurrences and scandals impacted the company and the effectiveness of the mitigation efforts the firm has utilized. This paper analyzes the financial profile of the American pharmaceutical giant Johnson and Johnson from 2017 to the present and addresses the company's performance in light of the various turbulences experienced in the hope of providing a solid view on whether to recommend advice against investing in the company.","PeriodicalId":208149,"journal":{"name":"Finance Educator: Courses","volume":"33 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Financial Analysis of Johnson & Johnson in Light of the COVID-19 Vaccination Research Developments\",\"authors\":\"Khalifa Alhosnai, Kaushang Kharbanda, Hessa Saeed Almazrouei, Asma Ibrahim Alzaabi, Wafaa Aldhanhani, Souhail Mostafa, Shaima Mohamed Alhajiri, Haitham Nobanee\",\"doi\":\"10.2139/ssrn.3896177\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Amid the recent developments regarding the Johnson & Johnson vaccination pause and investigation, an opportunity was created to observe and analyze the financial changes to the company's profile that had taken place as a result of the incident, to understand the impacts and effects of the decisions taken by the firm and previous occurrences and scandals impacted the company and the effectiveness of the mitigation efforts the firm has utilized. This paper analyzes the financial profile of the American pharmaceutical giant Johnson and Johnson from 2017 to the present and addresses the company's performance in light of the various turbulences experienced in the hope of providing a solid view on whether to recommend advice against investing in the company.\",\"PeriodicalId\":208149,\"journal\":{\"name\":\"Finance Educator: Courses\",\"volume\":\"33 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Finance Educator: Courses\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2139/ssrn.3896177\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Finance Educator: Courses","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2139/ssrn.3896177","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Financial Analysis of Johnson & Johnson in Light of the COVID-19 Vaccination Research Developments
Amid the recent developments regarding the Johnson & Johnson vaccination pause and investigation, an opportunity was created to observe and analyze the financial changes to the company's profile that had taken place as a result of the incident, to understand the impacts and effects of the decisions taken by the firm and previous occurrences and scandals impacted the company and the effectiveness of the mitigation efforts the firm has utilized. This paper analyzes the financial profile of the American pharmaceutical giant Johnson and Johnson from 2017 to the present and addresses the company's performance in light of the various turbulences experienced in the hope of providing a solid view on whether to recommend advice against investing in the company.